Ibrutinib and venetoclax are now listed in the interaction checker as cancer drugs and interactions can be found for all the comedications.
- Ibrutinib (Imbruvica®) is a Bruton’s tyrosine kinase inhibitor and is indicated for the treatment of mantle cell lymphoma, chronic lymphocytic B-cell leukemia and Waldenström macroglobulinemia.
- Venetoclax (Venclyxto®, Venclexta®) is a BCL-2 inhibitor and is indicated for the treatment of chronic lymphocytic B-cell leukemia.
